Impact of COVID-19 Response on Hepatitis Elimination in the Americas
The data presented focuses on the impact of the COVID-19 response on hepatitis elimination efforts in the Americas region. It includes information on changes in in-person clinic visits, declines in hepatitis B and C screening and treatment, and disruptions in opioid substitution therapy. The graphs and statistics highlight how the pandemic has affected healthcare services related to hepatitis in various countries across the Americas.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
Region of the Americas Impact of the COVID-19 Response on Hepatitis Elimination
Changes in In-Person Clinic Visit by Country 100% Percent Change in Clinic Visit Deferrals 76-99% 51-75% 26-50% 1-25% None United States of America United States of America United States of America United States of America United States of America United States of America United States of America United States of America United States of America United States of America United States of America United States of America United States of America United States of America United States of America United States of America Canada Canada Canada Canada Canada Canada Canada Ecuador Ecuador Mexico Mexico Mexico Mexico Argentina Argentina Argentina Argentina Argentina Peru Peru Peru Peru Peru Peru Peru Venezuela Guatemala Chile Panama Dominican Republic Colombia Colombia Paraguay Brazil Brazil Brazil Highest Impact Month Current Month Americas
Declines in Hepatitis B Treatment During Month of Highest Impact N=36 Declines in Hepatitis B Screening During Month of Highest Impact N=43 Unknown 7% Unknown 14% None 17% 100 5% None 21% 76-99 5% 100 8% 51-75 9% 76-99 11% 1-25 25% 1-25 21% 51-75 3% 26-50 32% 26-50 22% Americas Respondents asked to compare to typical month pre-COVID-19 N = Among respondents who indicated baseline HCV screening and treatment volumes
Declines in Hepatitis C Screening During Month of Highest Impact N=46 Declines in Hepatitis C Treatment During Month of Highest Impact N=40 100 9% None 15% None 7% 100 5%Unknown 76-99 6% 3% 76-99 23% 51-75 11% 1-25 27% 1-25 26% 51-75 13% 26-50 33% 26-50 22% Americas Respondents asked to compare to typical month pre-COVID-19 N = Among respondents who indicated baseline HCV screening and treatment volumes
Percent Disruptions in Opioid Substitution Therapy N=20 Unknown 10% None 15% 100% 15% 76-99% 5% 1-25% 25% 51-75% 5% 26-50% 25% Americas N = Among respondents who indicated baseline OST volumes
Changes in Hepatitis Clinical Services to Decrease COVID-19 Exposures Higher than global Deferred laboratory testing (Y) - 37 (71%) Higher than global Deferred imaging (Y) - 46 (87%) Lower than global Increase pill count per prescription (Y) - 23 (43%) Americas Among respondents who provide these services, excludes missing and N/A responses
Percent of Clinic Visits Conducted via Telemedicine 35 30 25 20 15 10 5 0 None 1-25% 26-50% 51-75% 76-99% 100% Highest Covid-19 Impact Month (N=54) Current Month (N=51) Americas
Communication of Facility Changes N=55 35 30 25 20 15 10 5 0 Individual Outreach Facility Announcemnet Radio Print Media American
Infection Control Procedures for Hepatitis Care During the Covid-19 Response N=55 50 45 40 35 30 25 20 15 10 5 0 Staff masksStaff gowns Cleaning Spacing Patient Masks Screening Phone Screening Other Americas
Challenges Preventing Facilities from Returning to Pre-Covid-19 Levels 25 20 15 10 5 0 Patient Anxiety Public Transport Limited Staff Inadequate PPE Loss of Space Loss of Staff Supply shortage Loss of Funding Americas
Global-Potential Benefits to Hepatitis Prevention, Care and Treatment 25 20 15 10 5 0 Improved Lab Platforms Improved Training Improved Reporting Improved Referral Network Improved Surveillance Improved Contact Tracing Demonstrating Value of Hepatitis Clinics Americas
Additional Strategies Reported in Open Responses Reviewing other physicians' records for people who have been identified with HCV in the past but who are still untreated. Doing electronic consultations for these individuals to get them going on treatment while still under the care of their regular provider. Physician, Canada Validating Dried Blood Spot testing for in home testing, gradually reinstituted opt-out HCV/HIV/HBV testing at intake, delivering/curbside medications for high risk individuals, dispensing full treatment course at initiation for HCV Physician, United States of America Blood draws on the porch on the side of our building Physician, United States of America Americas
Additional Strategies Reported in Open Responses Added the testing alert in May for all persons over the age of 18 get tested Physician, United States of America Working on self-testing initiative but not yet approved, Physician, Canada The telehealth platform was incredibly useful for the care of my patients with HIV and HCV. The patients were really happy with it, as were the providers. I would say that 40% of my patients could only partake by phone and not video; but I was still able to engage them effectively and started treatment by telehealth. It helped pt adherence and satisfaction. I think it is the ideal opportunity for HCV care. Physician, United States of America Americas
